Jenne Kyle 4
4 · IONIS PHARMACEUTICALS INC · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Jenne Kyle Exercises Options, Sells Shares
What Happened
Jenne Kyle, EVP and Chief Global Product Strategy Officer at Ionis Pharmaceuticals (IONS), exercised options to acquire a total of 37,277 shares (32,602 @ $46.10 and 4,675 @ $34.69) on March 10, 2026, and sold the same 37,277 shares that day in open-market transactions (21,191 @ $75.50 and 16,086 @ $76.30). Gross proceeds from the sales were about $2,827,325; the exercise payments totaled $1,665,128, implying roughly $1.16M pre-tax difference between sales proceeds and option exercise cost. The filing also shows the corresponding derivative instruments were disposed (reported at $0.00), indicating conversion of those instruments into the shares.
Key Details
- Transaction date: 2026-03-10 (Form 4 filed 2026-03-11 — timely; Form 4s are due within 2 business days)
- Acquired via exercise (Code M): 32,602 shares @ $46.10 ($1,502,952) and 4,675 shares @ $34.69 ($162,176) — total acquired 37,277 shares.
- Sold (Code S): 21,191 shares @ weighted avg $75.50 ($1,599,963) and 16,086 shares @ weighted avg $76.30 ($1,227,362) — total sold 37,277 shares; total sales ≈ $2,827,325.
- Footnotes: sales were made under a Rule 10b5-1 trading plan adopted Dec 8, 2025; reported sale prices are weighted averages with per-trade price ranges provided in the filing.
- Shares owned after transaction: not specified in the excerpt provided.
Context
This is a common “exercise-and-sell” (cashless) pattern: options were exercised and the resulting shares were immediately sold the same day. Sales executed under a 10b5-1 plan indicate the trades were prearranged rather than ad hoc. These transactions are routine insider liquidity events and should be viewed as such; they do not necessarily signal a change in the insider’s view of the company.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-10$46.10/sh+32,602$1,502,952→ 48,991 total - Sale
Common Stock
[F1][F2]2026-03-10$75.50/sh−21,191$1,599,963→ 27,800 total - Sale
Common Stock
[F1][F3]2026-03-10$76.30/sh−16,086$1,227,362→ 11,714 total - Exercise/Conversion
Common Stock
2026-03-10$34.69/sh+4,675$162,176→ 16,389 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-10−4,675→ 14,025 totalExercise: $34.69From: 2026-01-02Exp: 2035-01-01→ Common Stock (4,675 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-10−32,602→ 32,601 totalExercise: $46.10From: 2025-02-26Exp: 2034-02-25→ Common Stock (32,602 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.